B. Riley Expects Reduced Earnings for Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Analysts at B. Riley lowered their FY2026 EPS estimates for shares of Capricor Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. B. Riley analyst M. El-Saadi now forecasts that the biotechnology company will post earnings of $1.11 per share for the year, down from their prior estimate of $1.27. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54).

Several other research analysts also recently weighed in on CAPR. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Capricor Therapeutics in a research note on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. Finally, Roth Capital boosted their price target on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.38.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $5.77 on Thursday. Capricor Therapeutics has a 1 year low of $5.43 and a 1 year high of $20.75. The stock’s fifty day moving average price is $6.54 and its two-hundred day moving average price is $8.24. The firm has a market cap of $263.79 million, a PE ratio of -3.52 and a beta of 0.58.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in shares of Capricor Therapeutics by 2.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock valued at $1,079,000 after purchasing an additional 2,314 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 2,786 shares during the period. Deutsche Bank AG grew its position in Capricor Therapeutics by 10.9% during the first quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company’s stock worth $272,000 after buying an additional 2,822 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Capricor Therapeutics by 31.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company’s stock worth $126,000 after buying an additional 3,162 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 3,205 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.